Immunological drivers and potential novel drug targets for major psychiatric, neurodevelopmental, and neurodegenerative conditions
Christina Dardani(University of Bristol), Golam M. Khandaker(University of Bristol), George Davey Smith(University of Bristol), Tom G. Richardson(University of Bristol), Gibran Hemani(Bristol City Council), Jamie Robinson(Biogen (United States)), Dheeraj Rai(Avon and Wiltshire Mental Health Partnership NHS Trust), Evie Stergiakouli(University of Bristol), Tom R. Gaunt(MRC Epidemiology Unit), Alexandra Havdahl(Norwegian Institute of Public Health), Jakob Grove(Aarhus University), Renee M. Gardner(Karolinska Institutet), Hannah Jones(National Institute for Health and Care Research), Andrew M. McIntosh(Edinburgh Cancer Research)
Cited by 14
Related Papers
A reference panel of 64,976 haplotypes for genotype imputation
|Nature Genetics|2016|3.3k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Identification of common genetic risk variants for autism spectrum disorder
|Nature Genetics|2019|2.6k
Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder
|Nature Genetics|2018|2.3k